Lestaurtinib

Lestaurtinib

File:Lestaurtinib.png
Identifiers
PubChem CID	126565
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C26H21N3O4
Molar mass	439.462 g/mol

WikiDoc Resources for Lestaurtinib
Articles
Most recent articles on Lestaurtinib Most cited articles on Lestaurtinib Review articles on Lestaurtinib Articles on Lestaurtinib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lestaurtinib Images of Lestaurtinib Photos of Lestaurtinib Podcasts & MP3s on Lestaurtinib Videos on Lestaurtinib
Evidence Based Medicine
Cochrane Collaboration on Lestaurtinib Bandolier on Lestaurtinib TRIP on Lestaurtinib
Clinical Trials
Ongoing Trials on Lestaurtinib at Clinical Trials.gov Trial results on Lestaurtinib Clinical Trials on Lestaurtinib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lestaurtinib NICE Guidance on Lestaurtinib NHS PRODIGY Guidance FDA on Lestaurtinib CDC on Lestaurtinib
Books
Books on Lestaurtinib
News
Lestaurtinib in the news Be alerted to news on Lestaurtinib News trends on Lestaurtinib
Commentary
Blogs on Lestaurtinib
Definitions
Definitions of Lestaurtinib
Patient Resources / Community
Patient resources on Lestaurtinib Discussion groups on Lestaurtinib Patient Handouts on Lestaurtinib Directions to Hospitals Treating Lestaurtinib Risk calculators and risk factors for Lestaurtinib
Healthcare Provider Resources
Symptoms of Lestaurtinib Causes & Risk Factors for Lestaurtinib Diagnostic studies for Lestaurtinib Treatment of Lestaurtinib
Continuing Medical Education (CME)
CME Programs on Lestaurtinib
International
Lestaurtinib en Espanol Lestaurtinib en Francais
Business
Lestaurtinib in the Marketplace Patents on Lestaurtinib
Experimental / Informatics
List of terms related to Lestaurtinib

Overview

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders. It is an analog of staurosporine.

As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.

It is being developed by Cephalon.